HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dietmar W Siemann Selected Research

N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamide

5/2012Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
3/2012Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.
6/2010BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dietmar W Siemann Research Topics

Disease

76Neoplasms (Cancer)
02/2022 - 01/2002
18Neoplasm Metastasis (Metastasis)
09/2021 - 07/2005
11Prostatic Neoplasms (Prostate Cancer)
01/2019 - 05/2010
11Necrosis
03/2014 - 01/2002
10Sarcoma (Soft Tissue Sarcoma)
01/2014 - 05/2002
7Carcinoma (Carcinomatosis)
01/2018 - 11/2005
7Renal Cell Carcinoma (Grawitz Tumor)
06/2014 - 11/2004
6Breast Neoplasms (Breast Cancer)
01/2021 - 01/2013
6Hypoxia (Hypoxemia)
01/2019 - 09/2011
4Osteosarcoma (Osteogenic Sarcoma)
06/2021 - 01/2009
4Adenocarcinoma
01/2018 - 03/2010
4Ischemia
06/2004 - 05/2002
3Colorectal Neoplasms (Colorectal Cancer)
07/2006 - 06/2002
3Kaposi Sarcoma (Kaposi's Sarcoma)
11/2004 - 01/2002
2Leukemia
05/2016 - 09/2010
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/2009 - 07/2005
2Squamous Cell Carcinoma of Head and Neck
07/2005 - 01/2003
2Vascular Tissue Neoplasms
04/2004 - 01/2003
2Acquired Immunodeficiency Syndrome (AIDS)
01/2002 - 01/2002
1Acute Radiation Syndrome
01/2022
1Cardiotoxicity
08/2021
1Disease Progression
06/2016
1Glioblastoma (Glioblastoma Multiforme)
04/2015
1Neoplasm Micrometastasis
03/2014
1Vascular Diseases (Vascular Disease)
01/2014
1Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
04/2013
1Pathologic Neovascularization
01/2013

Drug/Important Bio-Agent (IBA)

13Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2016 - 01/2004
8Oxygen (Dioxygen)IBA
01/2019 - 11/2002
7Cathepsin LIBA
01/2021 - 10/2013
7Pharmaceutical PreparationsIBA
01/2018 - 05/2002
7Oxi 4503IBA
06/2014 - 07/2006
6Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2021 - 11/2010
6fosbretabulin (combretastatin A4)IBA
05/2007 - 01/2002
6N-acetylcochinol-O-phosphateIBA
11/2005 - 05/2002
5Proteins (Proteins, Gene)FDA Link
02/2022 - 07/2007
5Waste Products (Waste Product)IBA
01/2019 - 01/2003
5vandetanib (ZD6474)IBA
04/2015 - 11/2004
4KGP94IBA
09/2019 - 10/2013
4Small Interfering RNA (siRNA)IBA
09/2019 - 05/2010
4Cadherins (E-Cadherin)IBA
11/2016 - 05/2010
4vadimezanIBA
11/2010 - 05/2002
4Cisplatin (Platino)FDA LinkGeneric
11/2005 - 01/2002
3Phosphotransferases (Kinase)IBA
07/2020 - 06/2010
3Monoclonal AntibodiesIBA
01/2014 - 09/2006
3Angiogenesis InhibitorsIBA
01/2014 - 04/2004
3Bevacizumab (Avastin)FDA Link
05/2013 - 07/2008
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
08/2012 - 07/2006
3N- (4- (2- amino- 3- chloropyridin- 4- yloxy)- 3- fluorophenyl)- 4- ethoxy- 1- (4- fluorophenyl)- 2- oxo- 1,2- dihydropyridine- 3- carboxamideIBA
05/2012 - 06/2010
3Tyrosine Kinase InhibitorsIBA
06/2009 - 07/2006
2Conditioned Culture MediaIBA
01/2019 - 05/2012
2Caspase 3 (Caspase-3)IBA
01/2019 - 03/2014
2Dasatinib (BMS 354825)FDA Link
01/2018 - 02/2012
2Peptide Hydrolases (Proteases)FDA Link
06/2016 - 11/2015
2Biological ProductsIBA
11/2015 - 06/2004
2Dihydrotachysterol (AT 10)IBA
11/2015 - 01/2009
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2015 - 07/2006
2cediranib (AZD2171)IBA
04/2015 - 03/2009
2Hemoglobins (Hemoglobin)IBA
06/2014 - 01/2014
2Sunitinib (Sutent)FDA Link
06/2014 - 01/2014
2saracatinibIBA
08/2012 - 11/2010
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
05/2012 - 06/2010
2Proto-Oncogene Proteins c-metIBA
05/2012 - 06/2010
2bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
07/2006 - 05/2002
2EndostatinsIBA
01/2003 - 06/2002
1MicroRNAs (MicroRNA)IBA
02/2022
1IonsIBA
02/2022
1CalciumIBA
02/2022
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2022
1Peptides (Polypeptides)IBA
01/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
08/2021
1VimentinIBA
06/2021
1GangliosidesIBA
06/2021
1Therapeutic UsesIBA
06/2021
1Biomarkers (Surrogate Marker)IBA
06/2021
1bemcentinibIBA
01/2021
1tyrosine receptor (receptor, tyrosine)IBA
07/2020
1CathepsinsIBA
09/2019
1Oxidoreductases (Dehydrogenase)IBA
01/2019
1Cysteine Proteases (Cysteine Protease)IBA
01/2016
1ThiosemicarbazonesIBA
11/2015
1matrigelIBA
11/2015
1Vasoconstrictor AgentsIBA
04/2014
1Norepinephrine (Noradrenaline)FDA LinkGeneric
04/2014
1Gold Sodium Thiomalate (Sodium Aurothiomalate)IBA
03/2014
1AlbuminsIBA
01/2014
1Aldehyde Dehydrogenase 1 FamilyIBA
06/2013
1SmokeIBA
04/2013
1src-Family KinasesIBA
08/2012
1Adenosine Triphosphate (ATP)IBA
08/2012
1MEDI3617IBA
05/2012
1AngiopoietinsIBA
05/2012

Therapy/Procedure

40Therapeutics
02/2022 - 01/2002
13Radiotherapy
02/2011 - 01/2002
8Drug Therapy (Chemotherapy)
08/2021 - 01/2002
7Aftercare (After-Treatment)
06/2014 - 01/2002
3Nutritional Support (Artificial Feeding)
09/2015 - 04/2004
2Intramuscular Injections
01/2003 - 06/2002
1Lab-On-A-Chip Devices
06/2021
1Transplantation
11/2016